Burden of the Disease

Non-small cell lung cancer (NSCLC) accounts for around 85% of all lung cancers diagnosed. It is one of the most common cancers globally with over 2 million new cases reported annually. In the United States alone, NSCLC affects over 224,000 individuals each year according to recent cancer statistics. The high incidence of this disease has serious socioeconomic implications. While advances in treatment have modestly improved survival rates, NSCLC still has a 5-year survival rate of only 18%. This poor prognosis means the disease tends to impact individuals during their prime working years resulting in significant work absences and lost productivity.

Economic Cost of Treatment

Treatment for NSCLC poses a huge financial burden on both individuals and the healthcare system. Surgery, which is the main treatment option for early-stage NSCLC, can cost anywhere between $30,000 to $90,000 depending on the procedure. For later stage or advanced NSCLC, the preferred treatment is often chemotherapy. The cost of one cycle of chemo ranges from $5,000 to $15,000 on an average. Targeted therapies and immunotherapy drugs, which are now becoming standard of care for many Non-Small Cell Lung Cancer  patients, have a list price of over $10,000 per month. When combined with supportive care medications and periodic monitoring scans, the total medical expenditure for a single patient can rise to hundreds of thousands of dollars over the course of active treatment and follow-up. At a population level, the annual cost of lung cancer in the US is estimated to be over $24 billion as per American Lung Association figures.

Impact on Employers and the Workforce

NSCLC not only poses financial costs but also loss of productive man hours and employee absenteeism which negatively impacts businesses and the overall economy. Treatment schedules often require frequent hospital visits and prolonged sick leaves. Physical symptoms from the disease and side effects of therapy like fatigue, nausea etc. also impair daily functioning and work performance. A survey found NSCLC patients miss an average of 11 working days in the initial treatment phase and over 5 days in every follow-up year. This directly hits company revenues as well as coworker productivity due to increased workloads. In worst cases, lung cancer may force employees into early retirement or even result in job termination. This loss of trained, experienced workers then impacts operations and increases costs of rehiring and retraining replacements.

Rising Healthcare Insurance Premiums

As medical expenditures on NSCLC and other cancers continue expanding year-on-year, healthcare insurance providers are forced to regularly raise insurance premiums to keep up with rising costs. This severely affects businesses as higher premiums increase employee benefit expenses. A 2019 report showed employer sponsored family healthcare plans saw average annual premiums rise by over 5% from the previous year to reach $20,576. Insurance rate hikes disproportionately hurt small and medium enterprises with limited budgets. They often struggle to provide comprehensive coverage while continuing to attract skilled talent. Increased premiums are also passed on to employees in forms of higher co-pay deductions impacting their take-home income. If left unaddressed, uncontrollable growth in cancer healthcare costs pose a real threat to sustainability of employer-sponsored insurance schemes.

Impact on Wellness Programs

Preventive healthcare and wellness initiatives undertaken by companies to curb rising medical costs are hampered in presence of NSCLC and other lifestyle unrelated cancers. Resources spent on screening programs, smoking cessation drives etc. may not yield expected returns as incidence of such cancers cannot be controlled through behavioral modifications alone. This discourages further investments in such programs. It also influences design of incentive mechanisms linked to meeting health targets. Companies may be reluctant to penalize employees struggling with treatment of NSCLC or experiencing recurrences despite best efforts to maintain a healthy lifestyle. Alternative incentive structures focusing more on emotional wellbeing and work-life balance during illness may need consideration. Overall, incidence of NSCLC limits ability of businesses to impact healthcare spending through conventional wellness interventions.

Impact on National Economy

At a macroeconomic level, impacts of NSCLC like lost work hours, increased disability claims, higher insurance premiums, reduced productivity, costs of extended treatment and diminished workforce participation directly inflate healthcare costs for the nation. In US, annual projected costs of cancer to the economy was estimated at $216 billion as per one report. A large chunk is attributed to lung cancer owing to its high prevalence and treatment expenses. Reduced tax collections due to absenteeism, unemployment and lost incomes also affect government revenues. This strains public health budgets and limits funding for other developmental programs. With disease burden and costs projected to rise further worldwide owing to aging populations, untreated risks and expanding treatment options, NSCLC poses a serious threat to sustainability of global economies if not adequately addressed.

Concerted Action Needed

It is evident NSCLC exerts considerable financial burden on businesses as well as national economies. To curb this impact, coordinated multi-pronged strategies are needed involving stakeholders from public, private and non-profit sectors. Increased awareness about risks and early symptoms can boost screening rates helping detect tumors at curable stages. Smoothening approval pathways for cheaper generic drugs as well as supporting fast access to innovative immunotherapies may help lower costs of long-term care. Governments need to incentivize domestic pharmaceutical production while negotiating fair international drug prices. Employers can support wellness of NSCLC patients and caregivers through flexible work arrangements and mental health benefits. Collective efforts are required to decrease incidence and treatment expenditures of NSCLC to promote economic health aligned with public health goals.

Get more insights on This Topic- Non-Small Cell Lung Cancer